Comparative Pharmacology
Head-to-head clinical analysis: ANZEMET versus ZOFRAN PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZEMET versus ZOFRAN PRESERVATIVE FREE.
ANZEMET vs ZOFRAN PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emesis.
Selective 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, inhibiting emetic reflex.
100 mg orally once daily, or 1.8 mg/kg (maximum 100 mg) intravenously over 15 minutes once daily.
4-8 mg intravenously or intramuscularly as a single dose for prevention of chemotherapy-induced nausea and vomiting; 8 mg orally 30 minutes before chemotherapy, repeated every 8-12 hours as needed.
None Documented
None Documented
The terminal elimination half-life is approximately 5-7 hours in normal adults, but may be prolonged in patients with hepatic impairment (up to 11 hours) or severe renal impairment.
Terminal elimination half-life is approximately 3-6 hours in adults, but may be prolonged to 15-20 hours in severe hepatic impairment (Child-Pugh class C).
Approximately 70% of the dose is excreted in urine (mostly as metabolites, with less than 10% as unchanged drug) and about 20% in feces via biliary elimination.
Approximately 5% of ondansetron is excreted unchanged in urine; the remainder is extensively metabolized, with metabolites excreted in urine (46-60%) and feces (22-29%).
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)